This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
This webinar, hosted by DDW, explores how deep learning and physics-based methods can be combined to improve antibody affinity maturation and epitope mapping using workflows available in BIOVIA Discovery Studio Simulation on the 3DEXPERIENCE cloud platform. Through case studies involving antibody-antigen and nanobody-receptor complexes, the work demonstrates how virtual mutagenesis,… Read More
Nucleai and Gilead Sciences have entered an ongoing translational research collaboration, supporting Nucleai’s global antibody-drug conjugate (ADC) clinical development programmes. Nucleai’s AI-powered platform analyses pathology images to provide quantitative insights into tissue biology. As part of its collaboration with Gilead, Nucleai has analysed a large dataset of hematoxylin and eosin… Read More
Camena Bioscience has appointed Gregory McGuinness as CEO as it looks to scale its antibody discovery platform. The biotechnology company, which sees itself as a pioneer in enzymatic DNA synthesis for AI-driven antibody discovery, has appointed McGuinness to support the company’s growth, including its commercialisation of AI-driven antibody… Read More
Biotech Alchemab Therapeutics has extended its series A financing with a £25 million ($34 million) investment from the British Business Bank – the Bank’s largest investment in a life sciences company to date. The company says the funding will enable it to build its clinical pipeline and grow its antibody dataset to more… Read More
Thanks to their low toxicity and high specificity, therapeutic antibodies have enjoyed incredible market success across a range of disease categories. The global antibody discovery market, valued at $11.15 billion in 2025, is expected to surge to $35.35 billion by 2035. Experts predict this growth will… Read More
Download this exclusive eBook from Fluidic Sciences to learn more about: How the global antibody discovery market could evolve in the next 10 years How new technologies are improving efficiency and downstream success rates in antibody discovery Multiplexed rapid B cell screening and the future of antibody discovery… Read More
Dan Benjamin, Co-Founder & Chief Technology Officer of Immuto Scientific, examines why limited antibody–antigen co-structure datasets may be constraining AI model performance—and how high-throughput structural generation could reshape the field. Artificial intelligence now plays a central role in antibody discovery. Machine learning models assist in sequence… Read More
Download this In Focus report to learn about the market for antibody-based therapies and the scientific developments behind recent advances in these drugs. Read about: Where investment lies in the antibody-based drugs market Why mAbs are at the heart of phasing out animal testing The data bottleneck in AI antibody… Read More
‘JPM 2026’ certainly felt different to recent editions of the conference. The sky was blue – and the XBI had nearly doubled over the previous nine months. There’s nothing like a little winter sun and booming stocks to put a spring in an executive’s step! But questions over the robustness of the biopharma… Read More
Genmab has announced that the conditions to acquire all the issued and outstanding common shares of Merus for $97 per common share in cash have been satisfied. The company says the transaction diversifies its revenue and will drive sustained growth into the next decade. With… Read More
Novartis has entered into a definitive merger agreement with antibody oligonucleotide conjugates (AOCs) developer Avidity Biosciences. The acquisition will follow the separation of Avidity’s early-stage precision cardiology programmes into SpinCo, which is expected to be a publicly traded company. SpinCo will be led by Kathleen… Read More
